Selected Grants
(Neo)adjuvant IDE196 in patients with localized ocular melanoma [DAR-UM- 09] IDE196
Clinical TrialPrincipal Investigator · Awarded by IDEAYA Biosciences · 2023 - 2028IDE196-002
Clinical TrialPrincipal Investigator · Awarded by IDEAYA Biosciences · 2023 - 2028Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2023 - 2028A study of SGN BB228 in advanced melanoma and other solid tumors
Clinical TrialPrincipal Investigator · Awarded by Seagen, Inc · 2023 - 2028Regeneron R3767-ONC
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2023 - 2027(Neo)adjuvant IDE196 in patients with localized ocular melanoma [DAR-UM- 09] IDE196
Clinical TrialPrincipal Investigator · Awarded by IDEAYA Biosciences · 2023 - 2028IDE196-002
Clinical TrialPrincipal Investigator · Awarded by IDEAYA Biosciences · 2023 - 2028Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2023 - 2028A study of SGN BB228 in advanced melanoma and other solid tumors
Clinical TrialPrincipal Investigator · Awarded by Seagen, Inc · 2023 - 2028Regeneron R3767-ONC
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2023 - 2027A Study of Dapansutrile Plus Pembrolizumab in Patients with PD-1 Refractory Advanced Melanoma
Clinical TrialPrincipal Investigator · Awarded by Olatec Therapeutics LLC · 2022 - 2027IDE196 in Metastatic Uveal or Non-Uveal Melanoma with GNAQ/11 Mutations or PRKC Fusions (IDEAYA)
Clinical TrialPrincipal Investigator · Awarded by IDEAYA Biosciences · 2022 - 2026A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Clinical TrialPrincipal Investigator · Awarded by Bristoll Myers Squibb · 2022 - 2026Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
Clinical TrialPrincipal Investigator · Awarded by University of Pennsylvania · 2021 - 2026A Study of Dapansutrile Plus Pembrolizumab in Patients with PD-1 Refractory Advanced Melanoma
Clinical TrialPrincipal Investigator · Awarded by Merck & Co., Inc. · 2022 - 2026An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2021 - 2026A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2019 - 2025Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance
ResearchCollaborator · Awarded by Conquer Cancer Foundation · 2021 - 2024BMS Rollover (CA2098TT)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2019 - 2024A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2024A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2024A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Clinical TrialPrincipal Investigator · Awarded by Immunocore Limited · 2017 - 2024A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2021 - 2024A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2024BMS CA209-238-0025 A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at high risk for recurrence.
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2015 - 2024A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2024Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023Phase I Study of PF-07799933 (ARRY-440) as Monotherapy or in Combination in Participants With Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2023 - 2023A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melan
Clinical TrialPrincipal Investigator · Awarded by Immunocore Limited · 2016 - 2023A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2023CA209204 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2015 - 2021A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Clinical TrialPrincipal Investigator · Awarded by Array BioPharma Inc · 2019 - 2021A US Multi-Site Observational Study in Patients with Unresectable and Metastatic Melanoma: The OPTIMIzE Study
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2021DV3-MEL-01
Clinical TrialPrincipal Investigator · Awarded by Dynavax Technologies Corporation · 2017 - 2020Collaborative Success: Expanding Options for Patients with Melanoma
ResearchProject Lead · Awarded by National Institutes of Health · 1997 - 2019A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2017 - 2019An open label, multicenter, dose-escalation, phase 1B/2 study of the safety, efficacy, pharmacodynamics, and pharmacokinetics of RTA 408 in combination with IPILIMUMAB in the treatment of patients with unresectable or metastatic melanoma
Clinical TrialPrincipal Investigator · Awarded by Reata Pharmaceuticals, Inc. · 2014 - 2019INCB 24360-208 A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2018 - 2019A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody -Drug Conjugate, in Patients with Advanced Melanoma
Clinical TrialPrincipal Investigator · Awarded by Celldex Therapeutics, Inc. · 2015 - 2019A phase Ii trial of Neoadjuvant Ipilimumab follwed by Melphalan (L-PAM) via isolated Limb infusion (ILI) for patients with unresectable In-transit Extremity
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2018Expanded access of MK-3475 in metastatic melanoma patients with limited to no treatment options.
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2014 - 2015External Relationships
- Bristol Myers Squibb
- Pfizer Inc.
- Regeneron Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.